Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition

(2012) M. R. Rizzo et al.   DIABETES CARE

Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats

(2012) Wataru Inaba et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The future of incretin-based therapy: novel avenues-novel targets

(2011) B. Ahrén   DIABETES OBESITY & METABOLISM

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

(2011) B. Ahrén et al.   DIABETES OBESITY & METABOLISM

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

(2011) J. E. Foley et al.   DIABETOLOGIA

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice

(2011) Y. Takeda et al.   DIABETOLOGIA

Increased β-cell volume in mice fed a high-fat diet: A dynamic study over 12 months

(2011) Jonatan Ahrén et al.   Islets

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

(2010) A. D. Dobrian et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glucose regulation of β-cell stress in type 2 diabetes

(2010) G. Leibowitz et al.   DIABETES OBESITY & METABOLISM

Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice

(2010) X. Zhang et al.   DIABETES OBESITY & METABOLISM

Reversal of New-Onset Diabetes through Modulating Inflammation and Stimulating β-Cell Replication in Nonobese Diabetic Mice by a Dipeptidyl Peptidase IV Inhibitor

(2010) Lei Tian et al.   ENDOCRINOLOGY

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats

(2010) Alokesh Duttaroy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Combination Therapy with Nateglinide and Vildagliptin Improves Postprandial Metabolic Derangements in Zucker Fatty Rats

(2010) K. Miura et al.   HORMONE AND METABOLIC RESEARCH

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

(2010) Liliana Ferreira et al.   MEDIATORS OF INFLAMMATION

Age-Dependent Decline in  -Cell Proliferation Restricts the Capacity of  -Cell Regeneration in Mice

(2009) S.-I. Tschen et al.   DIABETES

Adaptive  -Cell Proliferation Is Severely Restricted With Advanced Age

(2009) M. M. Rankin et al.   DIABETES

Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and β-cell damage in diabetic mice

(2009) Y. Furuta et al.   DIABETES OBESITY & METABOLISM

The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation

(2009) M. Cnop et al.   DIABETOLOGIA

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

(2009) James Mu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation

(2008) S.-J. Kim et al.   DIABETES

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism

(2008) B. Ahrén et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE